Format

Send to

Choose Destination
Dement Geriatr Cogn Disord. 2007;23(2):116-9. Epub 2006 Dec 4.

A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.

Author information

1
Neuropharmacology Research Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. nathan.herrmann@sunnybrook.ca

Abstract

BACKGROUND/AIMS:

To assess the efficacy and tolerability of valproate for the treatment of agitation and aggression in moderate-to-severe Alzheimer's disease (AD).

METHODS:

This was a randomized, double-blind, placebo-controlled crossover trial of valproate in institutionalized AD patients. Patients were assessed with the Neuropsychiatric Inventory (NPI) and Cohen-Mansfield Agitation Inventory at baseline and after 6 weeks of treatment with valproate and placebo, with 2 weeks between phases to allow for placebo washout and tapering.

RESULTS:

Fourteen patients (8 male/6 female) aged 85.6 +/- 4.5 years with baseline Mini Mental State Examination scores of 4.5 +/- 4.6 and NPI agitation/aggression scores of 6.4 +/- 3.5 were randomized to treatment. NPI agitation/aggression treatment change scores significantly worsened during valproate treatment compared with placebo (Z = -2.03, p = 0.04). Tolerability of valproate was also poor, with patients experiencing a significantly greater mean number of adverse events during valproate therapy compared to placebo (Z = -2.82, p = 0.005).

CONCLUSION:

Valproate is not effective for the management of agitation in moderate-to-severe AD, and may be poorly tolerated in this population.

PMID:
17148938
DOI:
10.1159/000097757
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center